GlassScriptPhysician profile
Ernest Takang
NPI 1467738963
$1,878.63
in general payments reported to CMS, 2019-2025
13 companies · $84.76 in 2025
The $84.76 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.98 · 2022: $310 · 2023: $686 · 2024: $740 · 2025: $84.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $382.25 | 2022-2024 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $322.76 | 2023-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $272.29 | 2022-2024 | Fanapt |
| Sunovion Pharmaceuticals INC. | $158.17 | 2021-2022 | |
| Axsome Therapeutics, INC. | $153.75 | 2023-2024 | Auvelity |
| Abbvie INC. | $152.74 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $152.27 | 2022-2024 | Spravato, Invega Sustenna |
| Lundbeck LLC | $77.47 | 2022-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $69.41 | 2023 | Uzedy |
| Alkermes, INC. | $55.28 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.47 | 2022-2023 | |
| Indivior INC. | $22.32 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Takang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.